Hepatocellular Carcinoma Proteomics and Survival Data

Table 1 from a 2026 figshare study by Jianing Wang contains clinical and proteomic data from 201 patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors and targeted therapy. The dataset includes results from propensity score matching of 60 patient pairs and Olink proteomic analysis of 92 inflammatory proteins from 72 baseline plasma samples. It focuses on identifying plasma protein biomarkers, particularly IL-17A, associated with overall survival in patients with hyperbilirubinemia.

Use Cases

• Assess the association between elevated plasma IL-17A levels and poor overall survival in hyperbilirubinemia patients using Cox regression.
• Compare objective response rate and disease control rate between hyperbilirubinemia and normal bilirubin patient groups after propensity score matching.
• Identify differentially expressed inflammatory proteins from Olink proteomic analysis of 72 baseline plasma samples.
• Validate the interaction effect where high IL-17A amplifies poor prognosis specifically in the presence of hyperbilirubinemia.

Strengths

• Clinical data from 201 enrolled patients with advanced hepatocellular carcinoma.
• Proteomic quantification of 92 inflammatory proteins from 72 patient plasma samples.
• Propensity score matching created 60 comparable patient pairs for analysis.
• Study identifies 36 differentially expressed proteins between patient groups.

Limitations

• Small sample size for proteomic analysis (72 patients).
• Dataset is a single summary table (23.0 KB), not the underlying patient-level records.
• Geographic and demographic coverage of the patient cohort is unknown.

Provenance

Source

figshare, author Jianing Wang.

Collection Method

Data collected from a clinical study of patients receiving PD-1 inhibitor plus targeted therapy, with plasma protein analysis via Olink proteomics.

Time Range

null

Freshness

Last updated in April 2026.

Geography

null